Lacrimal Devices Market By Device Type (Implantable Devices {Punctal plugs, Lacrimal stents, Tubes}, Surgical Devices {Lacrimal probes, Balloon catheters, Dacryocystorhinostomy (DCR) instruments}, Moisture Retention Devices {Moisture goggles and Hydrating masks, Tear Stimulation Devices, and Others), By Application (Dry Eye Treatment, Nasolacrimal Duct Obstruction, and Others), By Distribution Channel (Direct Sales, Retail Pharmacies, and Online Pharmacies), By End-User (Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Lacrimal Devices market accounted for USD 160.5 Million in 2024 and is expected to reach USD 244.5 Million by 2035, growing at a CAGR of around 3.9% between 2025 and 2035. The Lacrimal Devices Market consists of medical devices intended to treat the disorders related to the tear duct system, focusing on dry eye syndrome and other eye-related ailments. Such technologies include surgical instruments for intensive treatment and punctal fillers inserted into punctae to stop tears from running freely. This market is fuelled by the increasing awareness of the population regarding eye health, the rising number of ocular diseases, and the enhancement of technologies that facilitate the treatment. Key players in this market involve manufacturers of surgical and non-surgical solutions aimed at the geriatric population due to increasing incidences of eye disorders.

Report Scope:

Market Dynamics

Prevalence of eye disorders boosts device demand significantly

The Lacrimal Devices Market is influenced by the increasing number of eye illnesses globally, especially dry eye syndrome and rare diseases that necessitate high tear production and drainage solutions. The awareness of eye health and the technological advancement in medical devices further fuel this demand. Lacrimal devices are consumed because older patients are experiencing ocular conditions. The American Academy of Ophthalmology suggests that about 16 million people in the United States suffer from dry eye disease requiring treatment. Moreover, government support and the provision of funds for eye health research are bolstering innovation in lacrimal device development available for patients across the globe.

Availability of alternatives limits the expansion of lacrimal devices

The Lacrimal Devices Market has several limitations hindering its growth due to the presence of other effective management strategies for dry eyes and other disorders. Almost all patients prefer to use low-cost alternatives such as artificial tears and medications rather than undergo complex procedures. Furthermore, patients and healthcare practitioners may not favor the surgical procedures involved in implanting a lacrimal device due to complications and associated risks. Moreover, patients may hesitate to use these devices because of their high cost and the variations in reimbursement rates. These factors combine to create a disadvantage for the market expansion of lacrimal devices.

Telemedicine integration enhances follow-up and patient adherence to treatment

The integration of telemedicine brings enormous prospects to the market for lacrimal devices considering patient follow-up and treatment adherence. In the case of remote consultations, healthcare providers easily monitor the progress of patients, alter treatment regimes, and device education as required. When interactions occur in therapy, the chances of the patients complying with the prescribed treatments are high, particularly since patients seem to be receiving treatment.

Furthermore, telemedicine helps in the early diagnosis of problems to prevent them from developing into significant issues. Telehealth adoption is expanding due to a positive trend that presents opportunities for manufacturers and developers of lacrimal devices. They create new products that integrate with existing digital health solutions. This integration enhances patient care and fuels revenue growth.

Industry Experts Opinion

“Dry eye occurs when the eyes do not produce an adequate amount of tears or when the tears evaporate from the surface of the eye too quickly. This condition manifests in various symptoms, including eye discomfort, reduced or excessive tearing, redness, itching, and a gritty sensation. These symptoms have the potential to induce headaches”,

• Dr. Madhura Tamhankar, Neuro-ophthalmologist at University of Pennsylvania School of Medicine.

Segment Analysis

Based on the product type, the Lacrimal Devices Market is classified into Implantable Devices, Surgical Devices, Moisture Retention Devices, Tear Stimulation Devices, and Others. Implantable devices are the dominant device type in the Lacrimal Devices Market. These devices, namely punctal plugs and drainage tubes are made for patients suffering from dry eye conditions or excessive tear drainage.

Such devices have gained popularity among patients and ophthalmologists since they improve the retention of tears and patient comfort. Furthermore, advancements in biocompatible materials and design innovations continue to boost the adoption of implantable devices and solidify their dominance in the market.

Based on the application, the Lacrimal Devices Market is classified into Dry Eye Treatment, Nasolacrimal Duct Obstruction, and Others. Dry Eye treatment is prominent in the Lacrimal Devices Market. This segment has witnessed significant growth due to the rising incidence of dry eye syndrome caused by the use of digital screens and other environmental factors.

Practitioners prefer punctal plug devices that improve lacrimal drainage because they are effective in reducing symptoms and improving tear retention. Furthermore, the prevalence of dry eye syndrome and the technological advancement of the devices are contributing to enhancing the growth of this segment, making it a prominent application area in the market.

Regional Analysis

The Lacrimal Devices Market is leading in North America due to the increasing incidence of dry eye syndrome and other eye disorders. Innovative product development, more ophthalmic treatments, and advanced healthcare facilities all contribute to this progress. Major companies in the market are investing in R&D to increase the effectiveness of the devices and ensure patient satisfaction. The growth is influenced by the elderly population and rising awareness about eye care. 

Lacrimal Devices Market expansion in the Asia-Pacific region is due to the high prevalence of eye-related diseases, including dry eye syndrome. Furthermore, an aging population, fast urban migration, and lifestyle changes drive the demand for advanced eye care. Improvements in the region's healthcare system and increased public awareness of eye health are encouraging market growth in Southeast Asia. Furthermore, major market players are concentrating on regional collaborations and application development to meet customer demands. The Asia-Pacific market is expected to grow at a faster rate as it adapts to the needs of people.

Competitive Landscape

Lacrimal Devices Market is competitive, including key players like Abbott Laboratories, Bausch + Lomb, Alcon, etc. New updates have focused on the recent development of comfortable and effective tear duct and punctual plug devices. For instance, Santen Pharmaceutical has introduced an innovative punctual plug design that helps to retain tears for an extended period. Bausch + Lomb has launched a line of biocompatible punctual devices. Alcon adopted a strategy of expanding its product lines through mergers and acquisitions to gain a firm presence in the industry. Due to the growing need for treatment alternatives for disorders affecting the lacrimal system, each of these companies is constantly improving its range of products.

Lacrimal Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In April 2024, "SOFT PLUG Extended Duration 180 T-Tapered Plug," a treatment intended for dry eyes, was introduced by OASIS Medical, Inc. The company offers surgical procedures and dry eye patient solution-based treatments.
• In August 2023, the European Medicine Agency (EMA) accepted the marketing authorization acceptance (MAA) for ciclosporin ophthalmic solution (CyclASol) for regulatory evaluation, according to a statement made by Novaliq GmbH, a biopharmaceutical firm that specializes in first- and best-in-class ocular therapies.

Report Coverage:

By Device Type

• Implantable Devices
  • Punctal plugs 
  • Lacrimal stents 
  • Tubes
• Surgical Devices
  • Lacrimal probes
  • Balloon catheters 
  • Dacryocystorhinostomy (DCR) instruments
• Moisture Retention Devices
  • Moisture goggles
  • Hydrating masks
• Tear Stimulation Devices
• Others

By Application

• Dry Eye Treatment
• Nasolacrimal Duct Obstruction
• Others

By Distribution Channel

• Direct Sales
• Retail Pharmacies
• Online Pharmacies  

By End-User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers 

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Abbott Laboratories
• Bausch + Lomb
• Alcon
• Fresenius Kabi AG
• CooperVision
• Menicon Co., Ltd.
• EyeGate Pharma
• Santen Pharmaceutical Co., Ltd.
• Oculentis GmbH
• AcuFocus, Inc.
• Hoya Corporation
• OptiMedica Corporation
• MediNatura, Inc.
• TearScience
• Nidek Co., Ltd.

Frequently Asked Questions (FAQs)